AAP Policy Statement Update – Changes to AAP HPV Recommendations
The AAP has updated provider and parent resources to reflect the changes in the new policy statement, “HPV Vaccine Recommendations” published in the March 2012 issue of Pediatrics. Updates include the routine use of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) as a three-dose series in boys 11-12 years of age.
AAP Policy Statement Update – PCV13 recommendations
The AAP has updated their policy on prevention of infections from Streptococcus pneumoniae in infants and children. Recommendations include:
- Infants and children who have started the pneumococcal vaccine series with PCV7 should complete the series with PCV13 unless PCV7 is the only vaccine available.
- A single supplemental dose of PCV13 is recommended for all children ages 14-59 months who have already completed the PCV7 series. PCV13 should be given at least 8 weeks after the last dose of PCV7.
- PCV13 is recommended for children 60 through 71 months of age who have underlying medical conditions that increase their risk of pneumococcal disease or complications, whereas PCV7 was recommended for children at increased risk up to age 59 months
- A single does of PCV13 may be administered to children ages 6-18 years who are at increased risk for invasive pneumococcal disease, even through the vaccine is not licensed for children 6 years of age and older.
To review the entire policy statement click on recommendations for use of the newly licensed 13-valent pneumococcal polysaccharide protein-conjugate vaccine (Prevnar 13[PCV13], Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.
American Academy of Pediatrics